The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Survival following initiation of everolimus for second-line treatment of metastatic renal cell carcinoma: Prognostic factors in clinical practice and comparison to clinical trials.
Michael K.K. Wong
Consultant or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Pfizer
Eric Jonasch
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Sumanta Kumar Pal
Consultant or Advisory Role - Novartis
Honoraria - Novartis
James E. Signorovitch
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Novartis
Research Funding - employee of Analysis Group, Inc, which has received consulting fees from Novartis
Peggy L. Lin
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Novartis
Research Funding - employee of Analysis Group, Inc, which has received consulting fees from Novartis
Zhimei Liu
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Xufang Wang
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Kenneth W. Culver
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Jeffrey A. Scott
Employment or Leadership Position - Cardinal Health
Stock Ownership - Cardinal Health
Daniel J. George
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Nicholas J. Vogelzang
Employment or Leadership Position - US Oncology
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Bayer; PAREXEL International